Brind.

HHS and FDA regulatory changes regarding peptide access and classification

Picking up: 1 development in the last 24 hours, 3 in the last 7 days Updated yesterday

The latest in this situation

  1. HHS policy changes regarding peptide access are affecting Olympia's facility.
  2. Hims & Hers plans to offer peptides amid FDA staff opposition to policy changes.
  3. HHS policy allows peptides in compounding pharmacies despite FDA lack of approval, with RFK Jr. arguing for safer compounds.

How it started

HHS and FDA are investigating industry donations and issuing warnings regarding policy and substance classification.

1 report, 1 independent, last reported Aug 7. The briefing below covers this first event.

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

HHS and FDA are investigating industry donations and issuing warnings regarding policy and substance classification.

Who's involved

What this event is mainly about
Department of Health & Human ServicesFDARobert F. Kennedy Jr.

How it developed

Newest first. Tap a step to see who reported it.
  1. HHS policy allows peptides in compounding pharmacies despite FDA lack of approval, with RFK Jr. arguing for safer compounds.Sub-event
  2. HHS and FDA are investigating industry donations and issuing warnings about policy and substance classification.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped